Compare DHI & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHI | ILMN |
|---|---|---|
| Founded | 1978 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.6B | 37.0B |
| IPO Year | 1995 | 2000 |
| Metric | DHI | ILMN |
|---|---|---|
| Price | $137.06 | $265.72 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 18 | 21 |
| Target Price | $159.83 | ★ $202.65 |
| AVG Volume (30 Days) | 2.2M | ★ 2.3M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | ★ 7.45 | 2.22 |
| Revenue | ★ $34,250,400,000.00 | $4,343,000,000.00 |
| Revenue This Year | N/A | $6.47 |
| Revenue Next Year | $5.13 | $6.40 |
| P/E Ratio | ★ $18.86 | $123.85 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $131.75 | $88.00 |
| 52 Week High | $176.22 | $278.99 |
| Indicator | DHI | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 37.33 | 73.86 |
| Support Level | $133.16 | $116.43 |
| Resistance Level | $153.01 | N/A |
| Average True Range (ATR) | 3.26 | 12.31 |
| MACD | -0.18 | 3.27 |
| Stochastic Oscillator | 0.00 | 90.76 |
D.R. Horton is the largest homebuilder in the United States with operations in 126 markets across 36 states. D.R. Horton mainly builds single-family homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. The firm has majority ownership of Forestar Group, a publicly traded residential lot development company. D.R. Horton's headquarters are in Arlington, Texas.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.